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Context: Isoflavones found in soy products have a chemical structure similar to estrogen, leading to
concerns of an adverse estrogenic effect in men, particularly in those with type 2 diabetes mellitus
(T2DM) who have low testosterone levels due to hypogonadism.
Objective: The primary outcome was change in total testosterone levels. The secondary outcomes
were the changes in glycemia and cardiovascular risk markers.
Design: This was a randomized double-blind parallel study.
Setting: This study occurred in a secondary care setting in United Kingdom.
Participants: Twohundredmenwith T2DManda total testosterone level#12 nmol/Lwere included.
Intervention: Fifteen grams of soy protein with 66 mg of isoflavones (SPI) or 15 g soy protein alone
without isoflavones (SP) daily as snack bars for 3 months were administered.
Results: There was no change in either total testosterone or in absolute free testosterone levels with
either SPI or SP. There was an increase in thyrotropin (TSH) and reduction in free thyroxine (fT4; P ,
0.01) after SPI supplementation. Glycemic control improved with a significant reduction in hemo-
globin A1c (24.19 [7.29]mmol/mol, P, 0.01) and homeostasismodel of assessment - insulin resistance
after SPI. Cardiovascular risk improved with a reduction in triglycerides, C-reactive protein, and
diastolic blood pressure (DBP; P , 0.05) with SPI vs SP supplementation. There was a 6%
improvement in 10-year coronary heart disease risk after 3 months of SPI supplementation.
Endothelial function improved with both SPI and SP supplementation (P , 0.01), with an increased
reactive hyperemia index that was greater for the SPI group (P , 0.05).
Conclusions: Testosterone levels were unchanged and there was a substantial improvement in
glycaemia and cardiovascular risk markers with SPI compared with SP alone over 3 months.
There was also a substantial increase in TSH and a reduction in fT4. (J Clin Endocrinol Metab 102:
425–433, 2017)
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Production and consumption of soy foods withinWestern countries have increased dramatically in the
past decade, with the postulated health benefits including
improvement in bone health, relief of menopausal
symptoms, and reduced risk of certain types of cancers
(1). In addition, habitual intake of soy isoflavones has
also been associatedwith a reduced risk of type 2 diabetes
mellitus (T2DM) and cardiovascular disease (CVD) (2),
which is of particular relevance given the increasing
global prevalence of diabetes.
However, there are concerns because isoflavones
have a chemical structure similar to estrogens and can
transactivate estrogen receptors, exerting estrogen-like
effects in vitro and in vivo (3). Isoflavones have been
shown to affect reproductive health in animals. Male rats
exposed to maternal dietary isoflavones through gesta-
tion and lactation exhibited a decrease in the anogenital
distance, testis size, and serum testosterone levels (4).
Dietary feeding of isoflavones in male mice resulted in
reduced plasma testosterone concentrations, atrophy of
seminiferous epithelium and accessory sex glands, and
squamous metaplasia of seminal vesicles (5). When fed
with soy, infant marmoset monkeys showed an increase in
testicular size and lower testosterone levels, suggesting a
potential “compensated Leydig cell failure” (6). This has
raised concerns regarding possible adverse effects of iso-
flavones in men, including feminization and infertility (7).
Testosterone levels in men with T2DM are lower from a
combination of factors, including insulin resistance and
obesity, which may make these individuals more suscep-
tible to isoflavone-mediated adverse effects (8). Therefore,
given the estrogenic effect of phytoestrogens, we hy-
pothesized that a detrimental estrogenic effect of soy with
and without isoflavones on testosterone levels would be
exaggerated in men who had low testosterone levels;
therefore, this randomized double-blind, parallel study
was undertaken in men with T2DM and compensated
hypogonadism.
Research Design and Methods
Two hundred men aged between 45 to 75 years with an early
morning total testosterone level,12 nmol/L (normal range, 12
to 25 nmol/L) (at least on 2 different occasions) with normal
gonadotrophins and hemoglobin A1c (HbA1c) ,9% (normal:
,6.5%) were recruited after screening 412 Caucasian male
patients with T2DM. Thesemenwere randomized either to 15 g
soy protein with 66 mg of isoflavones (SPI) per day or 15 g soy
protein alonewithout any isoflavones (SP) per day for 3months.
Studies of isoflavones intakes in Western countries indicate
an average daily intake of approximately 2 mg isoflavones;
vegetarians have a higher daily isoflavone intake of 16 mg and
Asian populations consuming a high soy diet or people con-
suming soy supplements have a daily isoflavone intake of
around 50 to 90 mg (9). The isoflavone concentrations used in
this study reflected the daily intake of an Asian population
consuming a high soy diet or people consuming soy supple-
ments (10).
SP contained less than 300 parts per billion of isoflavones,
achieved by serial alcohol washing (Dishman Ltd, India) and
confirmed analytically by FERA (Sand Hutton, York, United
Kingdom). Subjects were on stable medications for T2DM,
hyperlipidemia, and hypertension for at least 3 months before
the study. Subjects with significant hepatic or renal impairment,
who were allergic to soy products, receiving a testosterone
replacement, or who had received antibiotics 3 months before
the study were excluded.
The primary outcome of this study was a change in tes-
tosterone levels. The secondary outcomes for this study were
changes in glycemic control and cardiovascular risk markers,
including insulin resistance, lipid profile, high-sensitivityC-reactive
protein (hsCRP), and endothelial function.
At randomization and during study visits, subjects were
instructed to maintain their level of physical activity through-
out the study. In addition, subjects were required to avoid food
products containing soy, alcohol, vitamin or mineral supple-
mentation, and over-the-counter medications. Dietary reinforce-
ment was undertaken at each visit, together with measurement of
plasma isoflavone levels to ensure adherence. Adherence with
study preparation was calculated by counting the returned snack
bars. All subjects gave their written informed consent. The study
was given ethical approval by the Research Ethics Committee
(East Yorkshire & North Lincolnshire Research Ethics Com-
mittee (reference 09/H1304/45).
Study product
Abar containing 7.5 g isolated soy protein powder (Solcon F;
Solbar Industries, Ashdod, Israel) with 33 mg of isoflavones
(Solgen 40, Solbar Industries) or 7.5 g of SPwas consumed twice
daily for 3 months. The soy protein and phytoestrogens were
supplied by Solbar Industries from a single batch that was
designated for the study. The trial product was packaged by
Halo Food Ltd, Swindon, United Kingdom. Randomization
based on a computer-generated randomization list was per-
formed by Essential Nutrition Ltd, Brough, United Kingdom,
who held the randomization codes.
Study measurements
At the beginning and end of the study, following an over-
night fast, weight and blood pressure were measured and blood
samples were collected. Blood pressure was measured after the
subjects had been seated quietly for at least 5 minutes with the
right arm supported at heart level. Blood pressure measure-
ments were performed using an automated device (NPB-3900;
Nellcor Puritan Bennett, Pleasanton, CA) during each study
visit. Two readings were obtained at the beginning of each visit
at least 1 minute apart and the average of the readings was
taken. Waist circumference was measured using a specific ab-
dominal circumference tape measure. The tape measure was
wrapped around the participant’s waist at the midway point
between the bottom of the ribs and the top of the iliac crest. The
participants were encouraged to breath naturally during the
procedure, relax their abdominal muscles, and not hold their
breath. Fasting venous blood samples were collected, separated
by centrifugation at 2000g for 15 minutes at 4°C, and the ali-
quots stored at 280°C within 1 hour of collection. Plasma
glucose was measured using a Synchron LX20 analyzer
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(Beckman-Coulter, High Wycombe, United Kingdom), and
serum insulin was assayed using a competitive chemilumines-
cent immunoassay performed using the DPC Immulite 2000
analyzer (Euro/DPC, Llanberis, United Kingdom). The co-
efficient of variation of this method was 8%, calculated using
duplicate study samples. The analytical sensitivity was 2mU/mL
Insulin resistance was calculated using the homeostasis model of
assessment-insulin resistance (HOMA-IR) (insulin 3 glucose)/
22.5) (11).
Blood samples for testosterone levels were taken before 9 AM.
Serum total testosterone was measured by isotope-dilution
liquid chromatography tandem mass spectrometry (LC-MS/
MS). Serum free testosterone was measured using equilibrium
dialysis by adding a tracer amount of tritium-labeled testos-
terone to serum and then dialyzed against a buffer whose ionic
composition was similar to that of serum. The percent of tracer
that crossed the dialysis membrane at equilibrium was taken as
percent free fraction. Absolute free testosterone was calculated
by multiplying total testosterone with percent free testosterone.
Total cholesterol, triglycerides, and high-density lipoprotein
cholesterol (HDL-C) levels were measured enzymatically
using a Synchron LX20 analyzer (Beckman-Coulter). Low-
density lipoprotein cholesterol (LDL-C) was calculated using
the Friedewald equation. Serum hsCRP was measured by the
high-sensitivity method on a Beckman DXC analyzer. All
thyroid assays were performed on an Abbott Architect i4000
immunoassay analyzer (AbbottDiagnosticsDivision,Maidenhead,
United Kingdom).
The phytoestrogens in serumwere extracted and analyzed by
LGC, Fordham, Cambridgeshire, United Kingdom, using
isotope-dilution LC-MS/MS (12). LC-MS/MS was conducted
using a Sciex 4000 Qtrap (Singapore) with separation achieved
using a C18 column and mobile phases of water and acetoni-
trile, both containing acetic acid. No column switching was
used. The calibration range for all analytes was 0.5 ng/mL
to 200 ng/mL, with quality control samples prepared at low
(1.5 ng/mL), medium (80 ng/mL), and high (150 ng/mL) con-
centrations, and analyzed to confirm the assay performance.
Incurred quality control samples of serum were also run in the
sample batches. The assay sensitivity for equol, daidzein, and
genistein were all 0.5 ng/mL. The interassay coefficient of
variations were ,6.8% for daidzein, ,6.1% for genistein,
and ,7.4% for equol. The intra-assay coefficient of variations
were , 7.2% for daidzein (3.9% at the lower limit of quan-
tification [LLOQ]), ,3.6% for genistein (7.5% at the LLOQ),
and ,8.0% for equol (8.9% at the LLOQ).
Reactive hyperemia peripheral arterial tonometry to assess
peripheral microvascular endothelial function was measured
using an EndoPat 2000 (Itamar Ltd, Caesarea, Israel) according
to the manufacturer’s instructions. The reactive hyperemic in-
dex (RHI), which is a measure for endothelial function, and the
augmentation index (AI), which is a measure for arterial stiff-
ness, was also assessed using the EndoPat 2000 device. Both
measures were calculated using a computerized automated al-
gorithm (software version 3.1.2) provided with the device. The
subjects were in the supine position for a minimum of
20 minutes before measurements, in a quiet, temperature-
controlled (22°C) roomwith dimmed lights. Theywere asked to
remain as still as possible and silent during the entire mea-
surement period. Each recording consisted of 5 minutes of
baseline measurement, 5 minutes of occlusion measurement,
and 5 minutes postocclusion measurement (hyperemic period).
Occlusion of the brachial artery was performed on the non-
dominant upper arm. The occlusion pressure was at least mm
Hg60 mm Hg above the systolic blood pressure (SBP). This
technique determines functional endothelial change by mea-
suring changes in digital pulse volume during reactive hyper-
emia in an operator-independent manner. RHI is the ratio of the
average pulse wave amplitude measured over 60 seconds,
starting 1 minute after cuff deflation, to the average pulse wave
amplitude measured at the baseline. The other arm served as a
control and the ratio was corrected for changes in the systemic
vascular tone. The AI is an indirect measure of arterial stiffness
and is calculated as augmentation pressure divided by pulse
pressure 3100 to give a percentage.
Cardiovascular risk was estimated by using the UK Pro-
spective Diabetes Study (UKPDS) Risk Engine, which is a
T2DM-specific risk calculator based on 53,000 patients years of
data (13).
Breast ultrasound was undertaken and assessed for each
subject before and after the study by a consultant radiologist
who was blinded to treatment; this was a safety measure to
assess enlargement of breast tissue because excess estrogen can
stimulate breast enlargement in males.
Statistical analysis
Baseline continuously distributed data are presented as
median (25th/75th centiles); categorical data by n (%). Based on
the variability of the testosterone (14), for a 1 nmol change in
total testosterone, it was calculated that 150 subjects would be
required to give 90% power and an alpha value ,0.0l.
Assuming a dropout rate of 33%, 200 patients were recruited
for this study. Given randomization to treatment, baselines were
not compared statistically (15–17). Within-group differences
(difference between 12-week values and baseline values) are
shown for each treatment group separately by a mean and a
standard deviation (SD). Between-group comparisons were
performed using the independent sample t test. The t test as-
sumes equal variance between groups, which is reported for
the 2 within-treatment groups separately. For all statistical
analyses, a 2-tailed P , 0.05 was considered to indicate sta-
tistical significance. Bonferroni corrections were not applied
(18). Statistical analysis was performed using the STATA sta-
tistical computer package (StataCorp, 2013release 13; College
Station, TX).
Results
Two hundred patients with T2DM and low testosterone
levels were recruited after screening 412 patients (Fig. 1).
Adherence of completed patients by counting returned
bars was 98%. Twenty-nine patients dropped out (15
patients in the SPI group and 14 patients in the SP group)
because of gastrointestinal intolerance to the bars (19
patients [SPI, 10; SP, 9]), nonadherence (6 patients [SPI,
3; SP, 3]), the need to take antibiotics for concurrent
illness (3 patients [SPI, 2; SP, 1]); and 1 patient (SP, 1) was
started on testosterone replacement for his erectile dys-
function. The baseline anthropometric, hormonal, and
biochemical parameters and isoflavone levels of the 2
groups are given in Table 1.
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There were no changes in weight, body mass index, or
waist circumference with either SPI or SP supplementa-
tion. There was a substantial reduction of DBP after both
SPI and SP supplementation, but there were no important
differences between groups. There was no change in SBP
in either group. There was a substantial increase (im-
provement) in RHI with SPI supplementation compared
with SP supplementation alone (Table 2).
The UKPDS cardiovascular risk engine showed a
significant 6% reduction in nonfatal and fatal coronary
heart disease risk, a significant 9% reduction in fatal
coronary heart disease risk, and suggested a significant
reduction in fatal stroke risk with 3 months of SPI sup-
plementation (Table 3).
There were substantial reductions in triglycerides and
hsCRP with SPI compared with SP supplementation;
however, therewere no changes in total cholesterol, LDL-C,
or HDL-C with SPI supplementation compared with SP
supplementation (Table 2).
There were no changes in serum total testosterone,
absolute free testosterone, follicle-stimulating hormone
(FSH), luteinizing hormone (LH), or estradiol with either
SPI or SP supplementation (Table 2). There was a sub-
stantial reduction inHbA1c, fasting glucose, fasting insulin,
and HOMA-IR with SPI vs SP supplementation (Table 2).
There was a substantial increase in TSHwith 3months
of SPI supplementation (mean [SD]), 1.81 [0.92] vs 3.23
[1.03] mU/L) compared with SP supplementation (1.82
[0.93] vs 1.96 [1.11] mU/L). There was also an important
decrease in free thyroxine (fT4) with 3 months of SPI
supplementation (12.68 [1.90] vs 11.09 [2.00] pmol/L)
compared with 3 months of SP supplementation (13.06
[1.74] vs 12.74 [1.62] pmol/L. However, there were no
relevant changes in free tri-iodo thyronine with 3 months
of either SPI or SP supplementation.
There was a substantial increase in TSH and a re-
duction in fT4 after SPI vs SP supplementation, but this
did not reflect in any changes in free tri-iodo thyronine
after either SPI or SP supplementation (Table 2).
There were important increases in daidzein, genistein,
and equol with SPI supplementation confirming adher-
ence, whereas no changes from baseline were seen with
SP supplementation (Table 4).
Discussion
There were no substantial changes in testosterone mea-
sured by the gold standard techniques of MS/MS and
absolute free testosterone measured by equilibrium di-
alysis, by SP with and without isoflavones after 3 months
treatment. Previous studies on soy supplementation have
shown conflicting results (19); however, the previous
studies were not designed to investigate testosterone as the
primary end point (19), and most used immunoassay (20)
rather than gold standard testosterone measurements.
There was also no substantial change in sex hormone–
binding globulin (SHBG) or albuminwith either SPI or SP
supplementation. Testosterone is bound to SHBG and
albumin in circulation. There were also no changes in
either FSH or LH after both preparations suggesting that
there was no important alteration of hypothalamic-
pituitary-gonadal axis with either preparation. There
were also no substantial changes in estrogen levels in
either group. Testosterone is converted into estrogen in
various tissues, including adipose tissue by aromatase en-
zyme (21) and could potentially cause gynecomastia. There
were no changes in volume of breast tissue in either group.
There was a substantial improvement in glycemic
control as evidenced by a reduction in HbA1c after
3 months of SP and 66 mg isoflavone supplementation.
There was also an important reduction of fasting glucose
and insulin after SPI, which was reflected by a 65% re-
duction in HOMA-IR in this group of men with T2DM
and low testosterone levels. In vitro studies have suggested
several mechanisms for a direct pharmacological action of
soy on glycemic control, including inhibiting intestinal
brush border uptake of glucose, having a-glucosidase
inhibitor actions and tyrosine kinase inhibitory actions,
changes in insulin receptor numbers and affinity, in-
tracellular phosphorylation, and alterations in glucose
transport (22). Estrogen has been suggested to participate
in glucose homeostasis by modulating the expression of
genes that are involved in insulin sensitivity and glucose
uptake (23). Further, estrogen is a major regulator of
Figure 1. Flow diagram of participants through the study.
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adipocyte development and adipocyte number and inhibits
lipogenesis by reducing the activity of lipoprotein lipase,
an enzyme that regulates lipid uptake by adipocytes (24).
Isoflavones may also affect glucose metabolism by non-
estrogen receptor-mediated mechanisms. For example,
isoflavones have been reported to have an antidiabetic
effect through activation of PPARs, nuclear receptors that
participate in cellular lipid homeostasis and insulin ac-
tion (25).
There were no changes in weight after 3 months of
either SPI or SP alone, indicating that insulin resistance
decreased independently of a change in weight that has
been suggested by others (26). This is supported by epi-
demiological data showing that, compared with Japanese
in Tokyo on a traditional soy diet, Japanese-Americans
have a higher prevalence of T2DM and insulin resistance
despite similar body mass index levels (27).
Therewas an important reduction inDBP of;2mmHg
with both SPI and SP for 3 months. Hypertension, esti-
mated to affect;1billion individualsworldwide, is amajor
risk factor forCVD.A4 to 5mmHg reduction in SBP and a
2 to 3 mm Hg reduction in DBP can reduce CVD risk by
8% to 20% (28). Dietary soy isoflavones have been sug-
gested to result in arterial vasodilatation, improvement in
endothelial function, and decreased blood pressure, per-
haps by a nitric oxide–dependent mechanism in animal
experiments (29).Ameta-analysis of 11 trials demonstrated
that soy isoflavone intake resulted in a mean decrease of
2.5mmHg for SBP and1.5mmHg forDBP comparedwith
placebo (30), although there was a significant heteroge-
neity between the studies; however, the reduction of DBP
here is in accord with those reports on a vasodilation
mechanism. Such an antihypertensive effect has been sug-
gested to be intrinsic to the amino acid composition of
protein, especially arginine in soy, through multiple mech-
anisms perhaps accounting for the decrease in blood pres-
sure that was independent of isoflavones treatment (31).
The UKPDS risk engine (13) that calculates coronary
heart disease and stroke risk in patients with T2DM
showed a substantial reduction in nonfatal and fatal
coronary heart disease risk reduction of 6% and re-
duction of fatal coronary heart disease risk of 9% with
3 months of SPI supplementation. There was a statis-
tically relevant reduction of fatal stroke risk with both
SPI and SP supplementation, but there were no changes
between the 2 groups. This is particularly important
in patients with T2DM who are at in increased risk of
heart disease and stroke.
Table 1. Baseline Parameters Between the SPI and SP Groups
Parameters SP1 Group (n = 100) SP Group (n = 100)
Age, y 52.0 (50.0, 55.0) 52.0 (50.0, 55.0)
Weight 100.1 (88.5, 112.3) 98 (85.7, 111.9)
Body mass index, kg/m2 31.8 (28.8, 34.7) 31.6 (29.2, 35.0)
Duration of diabetes, y 7.3 (4.2, 8.8) 7.9 (4.4, 9.1)
HbA1c, mmol/mol 56 (52, 60) 58 (53, 64)
Total testosterone, nmol/L 10.0 (8.6, 11.0) 9.4 (7.9, 11.0)
% free testosterone 2.7 (2.2, 3.0) 2.6 (2.3, 3.2)
Absolute free testosterone, nmol/L 0.209 (0.183, 0.236) 0.202 (0.167, 0.238)
SHBG, nmol/L 29.0 (23.0, 40.0) 31.0 (21.3, 39.0)
TSH, mU/L 1.6 (1.2, 2.4) 1.6 (1.2, 2.5)
fT4, pmol/L 12.0 (12.0, 14.0) 13.0 (12.0, 14.0)
fT3, pmol/L 4.6 (4.2, 5.0) 4.6 (4.2, 4.9)
Fasting glucose, mmol/L 139.5 (118.8, 160.7) 135.9 (115.2, 154.4)
Fasting insulin, mIU/mL 16.5 (9.9, 25.3) 18.0 (10.4, 28.6)
HOMA-IR 5.6 (3.6, 9.0) 6.2 (3.8, 9.7)
hsCRP, mg/L 2.1 (0.8, 3.9) 1.9 (0.9, 4.1)
TC, mmol/L 3.9 (3.4, 4.6) 3.8 (3.4, 4.5)
LDL-C, mmol/L 2.0 (1.7, 2.9) 2.0 (1.6, 2.7)
HDL-C, mmol/L 1.1 (0.9, 1.3) 1.0 (0.9, 1.2)
Triglycerides, mmol/L 1.4 (1.0, 2.1) 1.3 (0.9, 2.0)
FSH, IU/L 5.7 (4.0, 9.4) 6.0 (4.8, 8.5)
LH, IU/L 3.7 (2.4, 5.6) 3.8 (3.0, 5.0)
Estradiol, pmol/L 89.0 (72.0, 110.0) 81.5 (69.0, 99.3)
Daidzein, ng/mL 1.4 (0.6, 2.7) 1.9 (0.7, 4.3)
Genistein, ng/mL 2.6 (0.7, 5.7) 2.9 (1.3, 7.2)
Equol, ng/mL 0.1 (0.1, 0.1) 0.1 (0.1, 0.1)
Values are provided as medians (25th/75th centiles). To convert values for glucose to milligrams per deciliter, divide by 0.056; to convert values for insulin
to picomoles per liter, multiply by 6; to convert values for cholesterol to milligrams per deciliter divide by 0.0259; to convert values for triglycerides to
milligrams per deciliter divide by 0.0113.
Abbreviations: fT3, free tri-iodo thyronine; HbA1c, glycated hemoglobin; TC, total cholesterol; TG, triglycerides; TSH, thyroid-stimulating hormone.
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There was a substantial increase in the RHI with
SPI supplementation compared with SP supplementa-
tion. Endothelial dysfunction is an early predictor of
CVD (32) and can be measured using EndoPat, which is
nonoperator-dependent. In the Framingham study, an
important inverse relation was observed between endo-
thelial function as determined by the EndoPat (RHI) and
multiple cardiovascular risk factors (33). The RHI was
reported to be significantly decreased in patients with
coronary artery disease, hypertension, hyperlipidemia
and diabetes (34), and several studies have demonstrated
an improvement in endothelial function as a result of
lifestyle modification including diet (35). In a small study,
soy nuts were shown to have a modest effects on at-
tenuating endothelial dysfunction over 4 weeks in adults
with features of metabolic syndrome (36). In the current
study on patients with T2DM, there was a substantial
increase in RHI, suggesting potential favorable effects
of SPI combination on endothelial function and cardio-
vascular risk.
There was an important reduction in triglycerides with
SPI comparedwith the SP group. There were no substantial
changes in total cholesterol, LDL-C, and HDL-C with SPI
supplementation compared with SP supplementation.
Isoflavones were shown to be hypolipidemic in both
cynomolgus monkeys (37) and humans (38) in some, but
not all, studies (39). Ingestion of ethanol extract rich in
isoflavones increases the abundance of hepatic messenger
RNA for cholesterol 7a-hydroxylase (40) and LDL re-
ceptors in rats and play important roles in cholesterol
catabolism. A recent meta-analysis indicated that soy
isoflavones significantly reduced total cholesterol and
LDL-C, but do not change HDL-C (41). However, a
positive association between isolated soy isoflavones and
HDL-C has been documented in postmenopausal women
(42). On the other hand, SP enhances the expression of
the LDL receptor in hypercholesterolemic patients with
T2DM (43) and in animal studies (44). Moreover,
some previous studies have demonstrated that SP rather
than isoflavones contributes to the lipid-lowering and
hypocholesterolemic properties of soy (45). These dis-
crepancies could be attributed to basal lipid profile or
different study designs and treatment composition, such
as the use of mixed isoflavones of poor purity, glucoside
Table 2. Anthropometric, Metabolic, and Hormonal Parameters: Comparison Between SPI and SP
Supplementation at End of Study
Parameter
SPI Group SP Group
Difference of the
Difference Between
Groups (95% CI) P Value
Paired Difference
3 Mo vs Baseline
Mean (SD) P Value
Paired Difference
3 Mo vs Baseline
Mean (SD) P Value
Weight, kg 0.60 (6.83) 0.39 0.39 (9.23) 0.30 0.21 (–2.1, 2.6) 0.85
Body mass index, kg/m2 0.17 (2.03) 0.39 0.15 (3.32) 0.29 0.02 (–0.79, 0.83) 0.86
Waist, cm 0.68 (7.12) 0.36 20.70 (5.42) 0.50 1.38 (–0.54, 3.32) 0.15
SBP, mm Hg 22.32 (15.84) 0.09 24.1 (15.05) 0.07 1.77 (–2.79, 6.34) 0.44
DBP, mm Hg 22.47 (11.28) 0.03 21.04 (11.46) 0.05 21.42 (–4.79, 1.93) 0.40
RHI 0.30 (0.60) ,0.01 20.11 (0.56) ,0.01 0.19 (0.02, 0.36) 0.02
AI 0.01 (0.14) 0.72 20.05 (0.12) 0.07 0.05 (–0,01, 0.089) 0.09
HbA1c, mmol/mol 24.19 (7.29) 0.01 1.63 (7.62) 0.06 25.82 (8.09, –3.56) ,0.001
Fasting glucose, mmol/L 21.44 (1.61) ,0.01 0.59 (2.02) 0.09 22.03 (–2.58, –1.49) ,0.001
Fasting insulin, mIU/mL 210.96 (13.51) ,0.01 20.70 (25.78) 0.83 210.25 (–16.36, –4.14) 0.001
HOMA-IR 24.42 (5.73) ,0.01 0.78 (17.67) 0.69 25.21 (–9.1, –1.32) 0.009
TC, mmol/L 20.05 (0.60) 0.41 0.14 (0.55) 0.02 20.19 (–0.36, –0.02) 0.08
LDL-C, mmol/L 20.05 (0.49) 0.34 0.11 (0.47) 0.05 20.16 (–0.31, –0.77) 0.09
HDL-C, mmol/L 20.01 (0.13) 0.38 0.02 (0.14) 0.25 20.03 (–0.07, 0.01) 0.14
Triglycerides, mmol/L 20.78 (0.80) ,0.01 0.08 (0.82) 0.37 20.86 (–1.1, –0.62) ,0.001
hsCRP, mg/L 22.55 (4.35) ,0.01 20.13 (3.92) 0.74 22.41 (–3.65, –1.18) ,0.001
Total testosterone, nmol/L 0.05 (0.5) 0.30 0.11 (0.55) 0.06 20.06 (–0.22, 0.09) 0.42
% free testosterone 20.01 (0.44) 0.92 0.05 (0.37) 0.12 20.07 (–0.2, 0.05) 0.22
Absolute free testosterone, nmol/L 0.02 (0.04) 0.81 0.02 (0.06) 0.08 0 (–0.01, 0.02) 0.80
SHBG, nmol/L 20.26 (5.91) 0.67 21.10 (4.46) 0.07 0.84 (–0.72, 2.40) 0.29
FSH, IU/L 0.26 (1.59) 0.12 0.09 (1.06) 0.56 0.19 (–0.21, 0.61) 0.34
LH, IU/L 0.34 (1.17) 0.07 0.17 (1.34) 0.26 0.17 (–0.20, 0.54) 0.37
Estradiol, pmol/L 2.15 (23.23) 0.39 0.36 (20.43) 0.80 1.79 (–4.80, 8.38) 0.59
TSH, mU/L 1.42 (0.83) ,0.01 0.16 (0.64) 0.06 1.26 (1.04, 1.49) ,0.001
fT4, pmol/L 21.53 (2.69) ,0.01 20.36 (1.98) 0.09 21.16 (–1.89, –0.44) 0.002
fT3, pmol/L 0.05 (0.71) 0.54 20.09 (1.05) 0.43 0.14 (–0.13, 0.42) 0.30
P values from independent t test. Within-pair SD in parentheses. To convert HbA1c from mmol/mol to %: (x/10.929) + 2.15; to convert HbA1c from %
to mmol/mol: (y 2 2.15) 3 10.929; to convert glucose from mmol/L to mg/dL: (x * 18); to convert glucose from mg/dL to mmol/L: (y/18).
Abbreviations: CI, confidence interval; DHEAS, dehydroepiandrostenedione sulfate; fT3, free tri-iodo thyronine.
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instead of aglycone forms, and the concomitant presence
of proteins.
There was a substantial reduction of hsCRP that is an
important cardiovascular risk marker with 3 months of
combined SPI preparation compared with SP supple-
mentation. The effect of soy on CRP is variable. SPI
supplementation significantly improved CRP in post-
menopausal women with T2DM (2), whereas isoflavone
supplementation alone was ineffective (39), suggesting a
potential matrix effect (i.e., the combination of both soy
protein and isoflavones rather than either alone) between
SP and isoflavones on CRP.
There was a substantial increase in TSH and reduction
in fT4 with 3 months of combined SPI supplementation.
Soy consumption is associated with thyroid disorders
such as hypothyroidism, goiter, and autoimmune thyroid
disease (46). In vitro studies have demonstrated that
isoflavones inhibit thyroid peroxidase, an enzyme in-
volved in the synthesis of T3 and T4 (47). In a study
examining the effects of soy isoflavones, Fischer rat
thyroid cells (FRTLs) were treated with a combination of
SPI; it was found that there was a dose-dependent sup-
pression of iodide uptake in FRTLs, whereas isoflavone
alone was ineffective. SPI combination and isoflavone
(genistein) alone increased the 40-kDa thyroglobulin
fragment (a known autoimmunogen) and nonglycosylated
sodium/iodide symporter in the FRTLs that might con-
tribute to the higher incidence of thyroid dysfunction (48).
In patients with subclinical hypothyroidism, SPI combi-
nation has shown to increase the risk of developing overt
hypothyroidism (49). In women in early menopause, SPI
supplementation has been shown to significantly increase
TSH and reduce fT4, suggesting a detrimental effect on
thyroid function (50). In the current study, none of the
patients developed subclinical or overt hypothyroidism;
however, all patients had normal thyroid function tests at
baseline.
The dropout rate during the intervention was less than
expected (14.5%), with the most frequent reason for
participant withdrawal in both groups attributable to
palatability; however, these numbers are comparable to
other nutrition trials in patients with T2DM (51). There
was a substantial rise in plasma isoflavone levels with SPI,
confirming adherence, whereas plasma isoflavone levels
did not differ from baseline in the SP group, confirming
that they had not taken any exogenous isoflavones during
the study.
In conclusion, SP with and without 66 mg isoflavone
per day for 3 months did not have an effect on testos-
terone levels in men with T2DM, confirming its safety. In
addition, there were substantial improvements in both
glycemic control and cardiovascular risk markers, in-
cluding DBP, triglycerides, and hsCRP. These were re-
flected in a significant improvement in the calculated
coronary heart disease risk with SPI supplementation,
whereas there were no changes seen with SP supple-
mentation. However, there was an important increase in
TSHwith a reduction in free T4 after high-dose isoflavone
in combination with SP supplementation, suggesting a
potential adverse effect of soy on the thyroid.
Table 3. 10-Y Cardiovascular Risk ReductionUsingUKPDS Risk Engine After 3Months of SPI Supplementation
and SP Alone Supplementation
Parameters
SPI SP SPI-SP Difference
Pre vs Post SPI % Change P Value Pre vs Post SP % Change P Value P Value
Nonfatal and fatal
CHD risk (%
21.14 6 9.34 vs 19.86 6 8.84 26 6 12 0.01 22.13 6 7.65 vs 22.24 6 7.86 0.02 6 0.19 0.82 0.04
Fatal CHD risk, %) 14.07 6 7.18 vs 12.86 6 6.95 29 6 0.11 ,0.01 16.82 6 17.27 vs 16.89 6 18.22 0.02 6 0.22 0.86 0.03
Nonfatal and fatal
stroke risk, %
10.02 6 5.67 vs 9.84 6 5.65 22 6 0.11 0.13 10.53 vs 4.35 vs 10.27 vs 4.14 20.01 6 0.10 0.07 0.98
Fatal stroke risk, % 1.60 6 1.12 vs 1.51 vs 1.04 6 20.06 6 0.10 0.04 1.69 6 0.88 vs 1.55 6 0.77 20.04 6 0.23 0.05 0.76
Abbreviation: CHD, coronary heart disease.
Table 4. Comparison of Plasma Phytoestrogen Levels With SPI and SP Supplementation
Parameter
SPI Group SP Group
P Value
Paired Difference
P Value
Paired Difference
P Value
Difference of the Difference
Between Groups
(95% CI)
3 Mo vs Baseline
Mean (SD)
3 Mo vs Baseline
Mean (SD)
Daidzein, ng/mL 6.61 (7.24) ,0.001 0.91 (3.28) 0.34 7.24 (4.48, 17.70) ,0.001
Genistein, ng/mL 13.19 (9.77) ,0.001 0.90 (3.59) 0.26 14.58 (8.11, 27.66) ,0.001
Equol, ng/mL 1.69 (3.52) ,0.001 1.03 (1.25) 0.20 1.65 (1.26, 2.15) ,0.001
Daidzein, genistein, and equol are natural log-transformed.
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